Children are the future of the country and the hope of the nation. The healthy growth of children and adolescents has a bearing on the health of the whole people, social stability and family happiness. Paying attention to the healthy growth of children and adolescents and improving their health and well-being is an indispensable key link in promoting social harmony and stability.
In recent years, the field of children's health has been facing new challenges, with the proportion of common and frequent diseases in children declining and lifestyle diseases increasing. Based on the in-depth interpretation of national policies and the capture of children's health needs, Jinsai Pharmaceutical has increased R&D investment, and has the ability to develop innovative products such as biological drugs, chemical drugs, live bacteria drugs, and medical devices.
Since its establishment, Kinsey Pharmaceutical has focused on the field of child growth retardation, and has made major breakthroughs and achievements. As early as 1998, the R&D team led by Dr. Jin Lei overcame a number of technical problems and developed China's first recombinant human growth hormone powder injection, filling the gap in the field of gene medicine in China. In 2005, Kinsey Pharmaceutical broke the technical barriers and developed Asia's first recombinant human growth hormone water injection with natural structure; In 2014, Kinsey Pharmaceutical increased its innovation capabilities and launched the world's first PEG-based long-acting recombinant human growth hormone, which attracted wide attention from the international community.
Taking long-acting recombinant human growth hormone Kinsain as an example, its advent has extended the half-life of growth hormone from 2 hours to 32 hours, which can be said to be at the forefront of the world. At the same time, on the basis of retaining all the advantages of liquid preparations, Kinsain also significantly reduced the frequency of administration, from 365 injections a year to 52 injections, which enhanced the patient's willingness to take medication and improved medication compliance. With the world's first PEG growth hormone conjugation technology platform, Kinsais has achieved extremely low immunogenicity and zero detection of antibodies, and achieved better efficacy on the basis of ensuring safety.
In order to meet the development needs of the times, Kinsey Pharmaceutical has carried out transformation and upgrading, while continuing to serve growth retardation, it also pays attention to children's overall health in sexual development, overweight and obesity, respiratory and digestion, allergies and self-immunity, nerves and speech, and posture. For example, the development of ultra-long-acting monthly preparations of growth hormone and oral ** short innovative drugs to improve the efficacy of drugs while bringing children a more comfortable ** experience; Focusing on the whole process of diagnosis and treatment of precocious puberty, we have created a series of products such as rapid testing of sex hormones, as well as a series of long-acting gonadotropin-releasing hormone analogues for central precocious puberty.
Jinsai Pharmaceutical not only focuses on the field of children's health, but also invests a lot of research in other fields of human health, and has achieved certain results. For example, a three-dimensional layout is carried out for women's whole life cycle health, including assisted reproduction, menopausal health, and common diseases. At present, the first long-acting recombinant human follicle-stimulating hormone weekly preparation in China has entered the phase III clinical research stage; The world's exclusive dosage form of progesterone long-acting weekly preparation has been approved to officially enter clinical research. In the field of menopause and common female diseases, Kinsey has also laid out a rich product pipeline, and developed the world's first lyase and live bacteria to replace antibiotics to solve the problem of drug resistance. For women with stress urinary incontinence instead of surgery**, the development of related drugs is expected to become the only one in the world.
Through self-research + external cooperation, Kinsey Pharmaceuticals has created a series of leading R&D technology platforms to drive the development of innovative products, including protein drug long-term controlled release technology platform, ADC drug technology platform, special preparation technology platform, ultrasound and hydrogel technology platform and other technology platforms, combined with AI technology, covering all aspects of innovative drug design, screening, evaluation, process development and preparation, and through the deep integration of production, learning, research and medicine, and multi-party linkage, new concepts and technologies are continuously introduced and promoted. For the well-being of a wider population.